Clinical Trials on Meningococcal Vaccines

Total 1286 results

PATH

Completed

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

Meningococcal Vaccines

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
University of Florida

Completed

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility (MenBVaccine)

Meningococcal Vaccine

United States
International Centre for Diarrhoeal Disease Research...
Incepta Vaccine Limited

Completed

Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh.

Meningococcal Vaccine

Bangladesh
Pfizer

Completed

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Meningococcal Vaccine

United States, Canada, Finland, Italy, Poland, United Kingdom, Czech Republic, Germany
Pfizer

Completed

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Meningococcal Vaccine

Finland, Spain, Poland
Pfizer

Completed

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

Meningococcal Vaccine

United States
Pfizer

Completed

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Meningococcal Vaccine

United States, Finland, Czechia, Poland
Pfizer

Completed

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

Meningococcal Vaccine

United States, Denmark, Hungary, Czechia, Poland
Pfizer

Completed

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Meningococcal Vaccine

Spain, Germany, Finland, Czechia, Poland, Denmark, Sweden
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

Vaccines, Pneumococcal | Vaccines, Pneumococcal Conjugate Vaccine
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety and Immunogenicity Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old

ACYW135 Meningococcal Polysaccharide Vaccine
Assistance Publique - Hôpitaux de Paris

Completed

Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation (MENINGREF)

Hematopoietic Stem Cell Transplant | Meningococcal Vaccine

France
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

Vaccines, Pneumococcal Conjugate Vaccine

South Africa
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

Vaccines, Pneumococcal Conjugate Vaccine
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Prevenar Immunogenicity in High Risk Children

Vaccines, Pneumococcal Conjugate Vaccine
Pfizer

Terminated

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Meningococcal Vaccine

Spain, Germany, Greece
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)

Vaccines, Combined | Hexavalent Vaccine

Germany, Italy, Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil

Vaccines, Pneumococcal Conjugate Vaccine

Brazil
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants

Vaccines, Pneumococcal Conjugate Vaccine

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Vaccines, Pneumococcal Conjugate Vaccine

Canada
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

Vaccines, Pneumococcal Conjugate Vaccine

Philippines
GlaxoSmithKline

Completed

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Infections, Meningococcal | Meningococcal Vaccines

India, Lebanon, Philippines, Saudi Arabia
GlaxoSmithKline

Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

Infections, Meningococcal | Meningococcal Vaccines

Estonia, Germany, Spain
Pfizer

Completed

A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

Pneumococcal Vaccines | Pneumococcal Conjugate Vaccine

Japan
GlaxoSmithKline

Completed

Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children

Infections, Meningococcal | Meningococcal Vaccines

Germany, France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

Vaccines | Pneumococcal Conjugate Vaccine

Taiwan
Serum Institute of India Pvt. Ltd.

Completed

Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age (ACYWX-04)

Vaccine for Meningococcal Disease

India
University of California, Los Angeles
Centers for Disease Control and Prevention

Completed

Testing the Use of Prompts to Increase Adolescent Immunization Rates (AIMHi)

Pertussis | Influenza | Human Papillomavirus | Meningococcal Disease | Vaccine Preventable Diseases

United States
University of Oxford

Completed

Investigating Meningococcal Vaccines in Adults

Meningococcal Infections | Neisseria Meningitidis | Meningococcal Vaccines | Factor H-binding Protein, Neisseria Meningitidi

United Kingdom
Association Clinique Thérapeutique Infantile du...
Pfizer

Recruiting

National Bacterial Meningitis Study

Meningitis | Children, Only | Neonatal Infection | Meningococcal Vaccines | Pneumococcal Conjugate Vaccine | Antibiotic Treatment | H. Influenzae Vaccine | Case Fatality Rate

France
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Novartis Vaccines
GlaxoSmithKline

Completed

Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

Meningococcal Meningitis | Meningoccocal Disease

Hungary, Spain
Pfizer

Completed

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

Meningococcal Vaccine

Poland, Czechia, Turkey
Epicentre
University of Oslo; Norwegian Institute of Public Health; Medecins Sans Frontieres...

Completed

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Infections, Meningococcal | Meningitis, Meningococcic

Norway, Uganda
Centers for Disease Control and Prevention, China

Recruiting

Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 (QIV;PPV23)

Pneumococcal Vaccines | Safety | Influenza Vaccines | COVID-19 Vaccines | Immunogenicity, Vaccine

China
Bandim Health Project

Active, not recruiting

OPV as Potential Protection Against COVID-19

Mortality | COVID | Morbidity | Poliovirus Vaccine, Oral | Non-Specific Effects of Vaccines

Guinea-Bissau
Prof. Elizabeth Miller
Novartis Vaccines

Completed

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults (MenOccy)

Meningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup W

United Kingdom
Chiron Corporation

Unknown

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Meningococcal Disease; Meningococcal Meningitis

United Kingdom
Beijing Chaoyang District Centre for Disease Control...

Completed

Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old

Meningococcal
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Emergent BioSolutions
Centers for Disease Control and Prevention

Completed

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

United States
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Infection, Meningococcal

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Meningococcal Disease | Infections, Meningococcal

Colombia, Panama, Chile
GlaxoSmithKline

Completed

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study

Meningococcal Disease | Infections, Meningococcal

United States
Bandim Health Project

Enrolling by invitation

Measles Vaccination at Health System Contacts

Mortality | Measles Vaccine | Hospital Admission | Non-specific (Heterologous) Effects of Vaccines

Guinea-Bissau
EuBiologics Co.,Ltd

Completed

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Infection, Meningococcal

Korea, Republic of

Clinical Trials on Meningococcal Vaccines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations